The ATLAS trial included patients with bridging fibrosis and cirrhosis due to MASH and examined the efficacy of monotherapy versus various combination approaches, including firsocostat (an acetyl co-A carboxylase [ACC] inhibitor), cilofexor (an farnesoid-x receptor [FXR] agonist), or selonsertib (an apoptosis signal-regulating kinase 1 [ASK-1] inhibitor) over 48 weeks. This evidence concerns the gene MAP3K5 and metabolic dysfunction-associated steatohepatitis.